Market Closed -
Other stock markets
|
After market 12:05:14 pm | |||
281.5 EUR | -0.28% | 281.9 | +0.14% |
Apr. 30 | SARTORIUS : Target cut by -6.1% | |
Apr. 24 | SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 76.82 and 51.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.25% | 18.54B | A | ||
-46.16% | 2.65B | C+ | ||
+17.00% | 1.85B | - | - | |
-0.51% | 1.66B | - | ||
+26.03% | 1.23B | B+ | ||
-13.90% | 989M | - | ||
-21.76% | 896M | - | C- | |
-19.12% | 673M | B+ | ||
+7.08% | 490M | C+ | ||
-.--% | 300M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- Ratings Sartorius AG